Abstract 2594: AI-powered radiomics model predicts immune checkpoint inhibitor-related pneumonitis (CIP) in advanced NSCLC patients

Abstract Background: With the escalating integration of immunotherapy in the management of advanced non-small cell lung cancer (NSCLC), the emergence of adverse events, particularly immune checkpoint inhibitor-related pneumonitis (CIP), poses important challenges. CIP is not uncommon and can be life-threatening. It often necessitates the discontinuation of immunotherapy, even in patients with an otherwise favorable response. Prevention, early detection and early management of CIP can enhance patient outcomes, yet no such predictive models have been established. This study investigates the use of Artificial Intelligence (AI) algorithms in analyzing radiomic features for the prediction of CIP in NSCLC patients receiving immunotherapy. Methods: A cohort of 105 stage III-IV NSCLC patients receiving immunotherapy was examined. Half of the patients were randomly split to a training set, while the remaining half were reserved for algorithm testing. The manual segmentation was performed by three physicians annotating in consensus using LIFEx software v7. 3. 0 (IMIV/CEA, Orsay, France). The Picture Health Px platform was utilized to perform an AI-powered deep phenotyping of the tumor and its surrounding habitat. A number of interpretable feature measures were extracted from baseline CT scans, which were in turn used to train a deep learning classifier for the detection of pneumonitis. Weighting techniques were applied to compensate for the imbalance of pneumonitis cases. Results: Among the 105 patients, 63 (60. 0%) received immunotherapy-only regimen and 42 (40. 0%) received combination immunochemotherapy. 18 (17. 1%) patients had pneumonitis events. Within this subset, 10 (55. 6%) had CIP. Among the CIP group, six patients (60. 0%) had grade 1 pneumonitis, three patients (30. 0%) had grade 2 pneumonitis, and one patient (10. 0%) had grade 3 pneumonitis, and none had grade 4 or grade 5 pneumonitis. Within the training set (n=51), the cross-validated area under the ROC curve (AUC) was 0. 71 (95% CI: 0. 68-0. 74). When applied to the test set, the model predicted pneumonitis with AUC=0. 63. Across the two datasets, the model correctly identified 4/6 (66. 7%) grade 1 pneumonitis events and 2/3 (66. 7%) grade 2 pneumonitis events, but misclassified the only available grade 3 event. Conclusion: The utilization of CT-based radiomic features demonstrates promise in predicting CIP in NSCLC patients undergoing immunotherapy. This approach holds potential for enhancing the identification and management of CIP, among NSCLC patients treated with immunotherapy. Citation Format: Seyoung Lee, Amogh Hiremath, Jeeyeon Lee, Peter Haseok Kim, Kai Zhang, Salie Lee, Monica Yadav, Maria J. Chuchuca, Taegyu Um, Myungwoo Nam, Liam Il-Young Chung, Hye Sung Kim, Jisang Yu, Trie Arni Djunadi, Leeseul Kim, Youjin Oh, Sungmi Yoon, Zunairah Shah, Yuchan Kim, Ilene Hong, Grace Kang, Jessica Jang, Amy Cho, Soowon Lee, Cecilia Nam, Timothy Hong, Yuri S. Velichko, Vamsidhar Velcheti, Anant Madabhushi, Nathaniel Braman, Young Kwang Chae. AI-powered radiomics model predicts immune checkpoint inhibitor-related pneumonitis (CIP) in advanced NSCLC patients abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts) ; 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84 (6Suppl): Abstract nr 2594.